wire - news in brief



Results 1 - 50 of 1631.
1 2 3 4 5 ... 33 Next »

Health - Pharmacology - 13.09.2021

Pharmacology - Health - 30.08.2021
Novartis Leqvio * (inclisiran) analyses show effective and sustained LDL-C reduction in two sub-populations of patients with ASCVD
Separate post hoc analyses of pooled Phase III ORION-9, -10 and -11 data show twice-yearly** Leqvio (inclisiran) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients with athe

Health - Pharmacology - 25.08.2021
Tailoring Treatment of Patients with the Lung Disease COPD
Patients with COPD are treated with drugs to improve the breathing ability in combination with inhaled corticosteroids to reduce the risk of acute worsening of the lung conditions. But the balance between reduced exacerbations and increased adverse effects of the drugs depends on the dose and on patient characteristics.

Pharmacology - Health - 24.08.2021
Novartis provides update on BELINDA study investigating Kymriah as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
Phase III BELINDA study did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12 mont

Pharmacology - Health - 18.08.2021
Rheon Medical is revolutionizing the surgical treatment of glaucoma
EPFL spin-off Rheon Medical has developed the world's first adjustable glaucoma drainage system, which has already been used successfully in over 250 patients in Europe.

Pharmacology - Health - 14.07.2021
Novartis announces NEJM publication of positive Phase III REACH3 data for Jakavi in chronic GvHD
REACH3 data show Jakavi significantly improved overall response rate (ORR) at week 24 (49.7% vs.

Health - Pharmacology - 08.07.2021
Shaping the Next-generation of Interventions for Malaria Prevention
Shaping the Next-generation of Interventions for Malaria Prevention
Together with the Bill and Melinda Gates Foundation, Swiss TPH has launched a new project bringing together research & development and implementation specialists, modellers and global-health experts to shape the next-generation of medical interventions for malaria prevention.

Pharmacology - Economics / Business - 28.06.2021

Pharmacology - Health - 23.06.2021
Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine
VISION manuscript shows that 177 Lu-PSMA-617 plus standard of care (SOC) significantly improved overall survival and radiographic progression-free survival for patients with metastatic castration-res

Pharmacology - Health - 18.06.2021
New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline
All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for =30 seconds, most (11/14) within the WHO wi

Health - Pharmacology - 16.06.2021
How do immune cells get activated?
How do immune cells get activated?
By studying the structure of cellular receptors and of the molecules that activate them, scientists at the Universities of Geneva and Basel are deciphering the details of immune cell activation. Chemokine receptors, located at the surface of many immune cells, play an important role in their function.

Pharmacology - Health - 16.06.2021

Pharmacology - Health - 11.06.2021
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-na´ve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intraand extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 na´ve paroxysmal noctu

Health - Pharmacology - 11.06.2021

Pharmacology - Health - 11.06.2021
Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years

Pharmacology - Health - 07.06.2021
Novartis announces new interim analysis Phase II data for iptacopan in rare kidney disease C3 glomerulopathy (C3G)
Data shows investigational iptacopan improved estimated glomerular filtration rate (eGFR) slope and stabilized kidney function in patients with C3G 1 ; Phase III clinical trial to start in 2021 Resul

Pharmacology - Health - 07.06.2021
Approval for New Alzheimer’s Drug Developed at UZH
The active ingredient aducanumab, which was discovered at the University of Zurich, has been approved for use in the United States as a treatment for Alzheimer's disease.

Pharmacology - Health - 06.06.2021
Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduc tion of proteinuria 1 - a key risk predictor in kidney disease progressi

Pharmacology - Health - 04.06.2021
Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June

Pharmacology - Health - 04.06.2021
Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-na´ve patients and 13.6 months in previously-treated patients in first published mature data 1,2

Pharmacology - Health - 03.06.2021
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.

Pharmacology - Health - 02.06.2021
Novartis Kisqali reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to th

Health - Pharmacology - 01.06.2021
The simulated patient
The simulated patient
Digital twins enable customized medical therapies. researchers have now modeled several hundred such avatars based on real people and treated them experimentally.

Pharmacology - Health - 01.06.2021
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo 1 The sa
1 2 3 4 5 ... 33 Next »